Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
grade D 2.42 4.31% 0.10
AFMD closed up 4.31 percent on Wednesday, February 26, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical AFMD trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Expansion Breakdown Bearish Swing Setup 4.31%
BB Squeeze Ended Range Expansion 4.31%
Below Lower BB Weakness 4.31%
Down 3 Days in a Row Weakness 4.31%
Down 4 Days in a Row Weakness 4.31%
Lower Bollinger Band Touch Weakness 4.31%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Medicine Biopharmaceutical Cancer Medical Specialties Solid Tumors Monoclonal Antibodies Lymphoma Glioblastoma Immunotherapies Chronic Lymphocytic Leukemia Seattle Genetics Head And Neck Cancer Hematologic Malignancies Non Hodgkin Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Cd30 Hodgkin Lymphoma

Is AFMD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.68
52 Week Low 2.18
Average Volume 713,512
200-Day Moving Average 2.85
50-Day Moving Average 2.71
20-Day Moving Average 2.64
10-Day Moving Average 2.59
Average True Range 0.16
ADX 18.1
+DI 11.08
-DI 28.08
Chandelier Exit (Long, 3 ATRs ) 2.38
Chandelier Exit (Short, 3 ATRs ) 2.76
Upper Bollinger Band 2.88
Lower Bollinger Band 2.40
Percent B (%b) 0.04
BandWidth 18.08
MACD Line -0.06
MACD Signal Line -0.03
MACD Histogram -0.0315
Fundamentals Value
Market Cap 106.33 Million
Num Shares 43.9 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -2.43
Price-to-Sales 22.02
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.65
Resistance 3 (R3) 2.62 2.53 2.61
Resistance 2 (R2) 2.53 2.47 2.54 2.59
Resistance 1 (R1) 2.47 2.43 2.50 2.50 2.58
Pivot Point 2.38 2.38 2.39 2.39 2.38
Support 1 (S1) 2.32 2.32 2.35 2.35 2.26
Support 2 (S2) 2.23 2.28 2.24 2.25
Support 3 (S3) 2.17 2.23 2.23
Support 4 (S4) 2.20